Northwire Canada EditionMonday, July 20, 2026
Sign inSubscribe
Northwire
⌕
KNOX 0.270 +0.0% TRO 0.135 −3.6% PX 0.120 −4.0% SDR 0.145 +45.0% SWA 0.035 +0.0% FNV 282.15 +0.3% GGA 4.55 −23.5% NICU 2.25 +1.1% KAPA 0.160 +6.7% HDRO 1.02 −2.9% LEAP 0.060 −7.7% TRCG 0.160 +3.2% TAJ 0.180 −2.7% NCAU 0.290 −4.9% APX 0.050 +0.0% RARE 9.10 +0.0% KNOX 0.270 +0.0% TRO 0.135 −3.6% PX 0.120 −4.0% SDR 0.145 +45.0% SWA 0.035 +0.0% FNV 282.15 +0.3% GGA 4.55 −23.5% NICU 2.25 +1.1% KAPA 0.160 +6.7% HDRO 1.02 −2.9% LEAP 0.060 −7.7% TRCG 0.160 +3.2% TAJ 0.180 −2.7% NCAU 0.290 −4.9% APX 0.050 +0.0% RARE 9.10 +0.0%
Earnings

Bausch Health to Announce Third Quarter 2025 Results on October 29

By The Northwire Desk — AI Analysis Sep 30, 2025 · 07:00 BHC · 9.01 BAUSCH HEALTH COMPANIES INC.
BHC · Price

Executive Summary

  • Bausch Health Companies Inc. will release its third‑quarter 2025 financial results after market close on Wednesday, October 29, 2025.
  • A live conference call and webcast will be held at 5:00 p.m. U.S. EDT to discuss the results and provide a business update.
  • All presentation materials will be posted in advance on the Investor Relations section of Bausch Health’s website; a replay will also be available thereafter.

Key Details

  • Release Timing: Q3 2025 financial results to be released after market close on 29‑Oct‑2025.
  • Conference Call: Live call/webcast scheduled for 5:00 p.m. U.S. EDT on the same day.
  • Access Link: Webcast will be streamed at http://ir.bauschhealth.com/events-and-presentations.
  • Materials Availability: Presentation slides and related documents will be posted on the Investor Relations website prior to the call; a replay will be posted afterward.
  • Company Overview (boilerplate removed): Bausch Health is a global diversified pharmaceutical company with products in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

Jun 09, 2026 · 08:00

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

Regulatory May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other Feb 23, 2026 · 17:59

Bausch Health launches Clear + Brilliant in Canada

Regulatory Feb 23, 2026 · 08:00

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

Production / Operations